FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
Patients experienced an elevated risk of venous thromboembolism both immediately before and immediately after giant cell arteritis diagnosis.
A retrospective analysis has shown that patients with ANCA-associated vasculitis treated with rituximab have a much lower risk of developing subsequent malignancies when compared with those treated with cyclophosphamide.
Treatment of giant cell arteritis or granulomatosis with polyangiitis with prednisolone or prednisone has been linked to elevated risks of type 2 diabetes early during treatment.
Tocilizumab (Actemra®,Genentech) is the first treatment proposed for giant cell arthritis in 50 years.
Distinctive presentations, histopathology, and therapeutic response in both KD and KLS suggest a common etiology.
Retrospectively acquired population-based data suggest that the incidence of VTE, stroke and TIA was similar in patients with GCA compared to those who did not have GCA.
Low IgG and B cell counts were associated with infection and vaccine response among patients with systemic vasculitis in stable remission.
Measuring IgG levels and B cell counts may identify high infection risk and help clinicians balance the risk of immunosuppression side effects and disease activity in patients with systemic vasculitis.
This is the first randomized placebo-controlled trial to demonstrate the induction and remission efficacy of IL-6 inhibition with tocilizumab in patients with giant cell arteritis (GCA).
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care